SCHEMBL4568191

SCHEMBL4568191

COC(=O)c1cccc(Cc2c(-c3ccc(C)s3)[nH]c3cc(OC)ccc23)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.40
MAPT P10636 4/20 0.40
ALDH1A1 P00352 3/20 0.40
HSD17B10 Q99714 3/20 0.40
ALOX15 P16050 2/20 0.40
GAA P10253 2/20 0.40
HPGD P15428 2/20 0.40
BACE1 P56817 1/20 0.40
USP2 O75604 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
PLA2G2A P14555 1/20 0.39
PTGS2 P35354 1/20 0.38
PARP1 P09874 1/20 0.38
DYRK1A Q13627 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GPR17 Q13304 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568228 0.92 GPR17 (0.42) KDM4EKMT2AMEN1PTGS2DYRK1A
SCHEMBL4568194 0.89 PTGS2 (0.38) KDM4EMAPTALDH1A1HSD17B10ALOX15
SCHEMBL4568180 0.88 MEN1 (0.41) KDM4EMAPTALDH1A1HSD17B10ALOX15
SCHEMBL4568185 0.86 PTGS2 (0.38) KDM4EMAPTALDH1A1HSD17B10ALOX15
SCHEMBL4568176 0.86 MDM4 (0.41) KDM4EMAPTALDH1A1HSD17B10ALOX15
SCHEMBL4568192 0.86 KDM4E (0.42) KDM4EMAPTALDH1A1HSD17B10ALOX15
SCHEMBL3706006 0.86 MTNR1A (0.48) KDM4EALDH1A1HSD17B10HPGDPLA2G2A
SCHEMBL4568174 0.85 MTNR1A (0.43) KDM4EMAPTALDH1A1HSD17B10ALOX15
SCHEMBL4568175 0.85 PTGS2 (0.42) KDM4EMAPTALDH1A1HSD17B10ALOX15
SCHEMBL4568188 0.84 KDM4E (0.40) KDM4EMAPTALDH1A1HSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2474530-B1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL (JP) 2014-09-03 EP disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R KDM4E 3521/4885MAPT 3199/4885ALDH1A1 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.